Related Experiment Videos
[Anti-arrhythmic drug prevention of sudden cardiac death--the status after the CAST study]
1Abteilung Innere Medizin III, Eberhard-Karls-Universität Tübingen.
Insights
Classical antiarrhythmic drugs increase mortality in sudden cardiac death patients due to proarrhythmic effects. New antifibrillatory drugs targeting the arrhythmogenic substrate are needed for effective prophylaxis.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Sudden cardiac death (SCD) is primarily caused by ventricular tachyarrhythmias.
- Antiarrhythmic drugs are used for prophylaxis, but classical agents (Class 1) show increased mortality.
- Proarrhythmic effects, particularly in patients with reduced left ventricular function, contribute to these adverse outcomes.
Purpose:
- To evaluate the efficacy and safety of antiarrhythmic drugs in preventing sudden cardiac death.
- To identify the limitations of classical antiarrhythmic drugs and explore alternative therapeutic strategies.
- To emphasize the need for drugs that modulate the arrhythmogenic substrate rather than merely suppressing arrhythmias.
Summary:
- Classical antiarrhythmic drugs (Class 1) have demonstrated increased mortality in patients treated for sudden cardiac death prophylaxis.
- Proarrhythmic effects are a significant concern, especially in patients with compromised left ventricular function.
- Current methods like Holter ECG and ventricular premature beat suppression are insufficient to predict or prevent lethal arrhythmias.
- The "arrhythmogenic substrate" is crucial for lethal arrhythmia induction, necessitating drugs that act as antifibrillatory agents.
Impact:
- Highlights the limitations of current antiarrhythmic drug therapy for sudden cardiac death prevention.
- Suggests a paradigm shift towards antifibrillatory drugs that target the underlying substrate.
- Identifies beta blockers and Class 3 drugs as promising initial steps in developing new therapeutic approaches.
Abstract:
Sudden cardiac death is caused by ventricular tachyarrhythmias. Therefore, antiarrhythmic drugs have been widely used in the prophylaxis of this lethal event. However, all studies using "classical" antiarrhythmic drugs (class 1) for this purpose have shown an enhanced mortality in the patients treated. One of the major causes for these disappointing results are probably proarrhythmic effects, which are especially observed in patients with reduced left ventricular function. Obviously a normal Holter ECG during the titration phase cannot exclude proarrhythmic events during long-term follow-up. In addition, the suppression of ventricular premature beats by an antiarrhythmic agent seems not to be an useful criterium as far as the prophylaxis of sudden death is concerned. The crucial prerequisit for the induction of the lethal arrhythmia is the "arrhythmogenic substrate" which clinically can only incompletely analysed by recording of late potentials or programmed ventricular stimulation. From the therapeutical point of view we need drugs which can modulate this arrhythmogenic substrate i.e. antifibrillatory acting drugs and not antiarrhythmic drugs in the classical sense. Beta blockers and class 3 drugs are the first step in this direction.